Loading
HKSEHealthcareBiotechnology
Latest quote
HK$44.94
−HK$0.22 · -0.49%
HJ Science Co., Ltd. is a clinical stage biotech company, which engages in research and development of small molecule drugs for tumors, autoimmune & metabolic system diseases for clinical treatments. It provides drug design, in vivo and in vitro activity evaluation, drug metabolism, synthesis, quality research, formulation development, and scale-up. Its products include HJ787, HJ178 and HJ891. The company was founded by Ji Jianxin on February 20, 2017 and is headquartered in Chengdu, China.
Latest quote
HK$44.94
−HK$0.22 · -0.49%
Regular session · HKT · Market data may be delayed.
HJ Science Co., Ltd. is a clinical stage biotech company, which engages in research and development of small molecule drugs for tumors, autoimmune & metabolic system diseases for clinical treatments. It provides drug design, in vivo and in vitro activity evaluation, drug metabolism, synthesis, quality research, formulation development, and scale-up. Its products include HJ787, HJ178 and HJ891. The company was founded by Ji Jianxin on February 20, 2017 and is headquartered in Chengdu, China.
Day range
Current HK$44.94
52-week range
Current HK$44.94
Regular session · HKT · Market data may be delayed.
HJ Science Co., Ltd. is a clinical stage biotech company, which engages in research and development of small molecule drugs for tumors, autoimmune & metabolic system diseases for clinical treatments. It provides drug design, in vivo and in vitro activity evaluation, drug metabolism, synthesis, quality research, formulation development, and scale-up. Its products include HJ787, HJ178 and HJ891. The company was founded by Ji Jianxin on February 20, 2017 and is headquartered in Chengdu, China.
Day range
Current HK$44.94
52-week range
Current HK$44.94
| Metric (HKD) | FY2025 |
|---|---|
| Revenue | 16.18M HKD |
| Gross profit | 16.18M HKD |
| Research and development | 136.41M HKD |
| Selling, general, and administrative | 35.03M HKD |
| Operating expenses | 171.44M HKD |
| Depreciation and amortization | 2.4M HKD |
| Operating income | −155.26M HKD |
| Net income | −167.25M HKD |
Company facts updated Sep 7, 2026.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
